Alefacept-treated patients showing slower T1D progression (R) preserved higher CD57+ Tex levels following treatment than patients showing more rapid disease progression, consistent with a role for CD57+ Tex in suppression of autoimmunity. The gene discussed is B3GAT1; the disease is Autoimmunity.